HP
CHRS icon

HealthInvest Partners’s Coherus Oncology CHRS Stock Holding History

HealthInvest Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-660,000
Closed -$9.64M – 10
2021
Q1 		$9.64M Buy
660,000
+60,000
+10% +$1.02M 7.68% 4
2020
Q4 		$10.4M Buy
+600,000
New +$10.7M 6.91% 2

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

HealthInvest Partners's CHRS Position: Q2 2021 in Review

HealthInvest Partners sold out of Coherus Oncology (CHRS) in Q2 2021, closing a stake of 660,000 shares — an estimated $9.64M sold.

HealthInvest Partners first reported a position in CHRS in Q4 2020 and held it in 2 quarters. The position peaked at $10.4M in Q4 2020. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2021.

  • HealthInvest Partners reported no remaining Coherus Oncology position as of Q2 2021 after selling out during the quarter.
  • HealthInvest Partners sold 660,000 Coherus Oncology shares in Q2 2021, an estimated $9.64M.
  • HealthInvest Partners first reported a position in Coherus Oncology in Q4 2020 and held it in 2 quarters.
  • HealthInvest Partners's Coherus Oncology position peaked at $10.4M in Q4 2020.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2021.

Based on HealthInvest Partners's 13F filing for Q2 2021, filed 10 Aug 2021.